Element Biosciences Stock

HealthTech

Looking to sell Element Biosciences Stock or Options? Get a free valuation

Founded: 2017Funding to Date: $685M

Element Biosciences is a biotechnology company focused on developing innovative and affordable DNA sequencing technologies. Their platform aims to deliver high-quality genomic data with greater accuracy and flexibility, catering to a wide range of research and clinical applications. Element Biosciences seeks to democratize access to advanced sequencing capabilities, driving progress in genomics and personalized medicine.

Investors Include:

Meritech Capital Partners, Samsung Electronics, Fusion Fund, Alexandria Venture Investments, Logos Capital, Foresite Capital, Janus Henderson Investors, JS Capital Management, Wellington Management, Venrock, RA Capital Management, T. Rowe Price Group, Morgan Stanley, Fidelity Management & Research.

Our available services for this company

*All loans issued by WebBank, member FDIC

Risk ReductionLate-Stage Exchange Fund

LiquidityExchange Loan*

Option ExerciseOption Exercise Loan*

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund

Management Team

Shawn Levy Ph.DChief Scientific Officer & Senior Vice President of Applications

Chief Scientific Officer & Senior Vice President of Applications

Molly He Ph.DCo-Founder, Chief Executive Officer & Board Member

Co-Founder, Chief Executive Officer & Board Member

Michael Previte Ph.DCo-Founder, Senior Vice President, Research & Development & Chief Technology Officer

Co-Founder, Senior Vice President, Research & Development & Chief Technology Officer

Matthew Kellinger Ph.DCo-Founder & Vice President of Chemistry

Co-Founder & Vice President of Chemistry

Yaron Hakak Ph.DSenior Vice President of Corporate and Business Development

Senior Vice President of Corporate and Business Development

Logan ZinserSenior Vice President of Finance & Administration

Senior Vice President of Finance & Administration

Brian StolzChief People Officer

Chief People Officer

Jordan NeysmithVice President of Engineering

Vice President of Engineering

John StuelpnagelChairman

Chairman

Board Members

Bryan Roberts Ph.DBoard Member

Board Member

James Tananbaum MDBoard Member

Board Member

Other HealthTech companies from Collective's Target Portfolio

Element Biosciences in the News

Source: Pulse 2.0Element Biosciences: Over $277 Million In Series D Raised For Democratizing Access To Advanced Biological Tools

Element Biosciences, a developer of pioneering technologies to empower science, announced over$277 millionin Series D funding to support its growing global customer base with disruptive DNA sequencing and multi-omics technologies for years to come...

Source: ChannelnewsIs Samsung Gearing Up For Large Mergers And Acquisitions?

Is Samsung Gearing Up For Large Mergers And Acquisitions?

Source: PR NewsWireElement Biosciences Raises Over $277 Million to Develop and Commercialize Differentiated Products and Continue Rapid Growth

/PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced over $277 million in Series D investment to...